Loading...
Loading...
RIGL| Name | Value |
|---|---|
| Revenues | 26.9M |
| Cost of Revenue | 1.1M |
| Gross Profit | 25.8M |
| Operating Expense | 31.1M |
| Operating I/L | -5.3M |
| Other Income/Expense | -1.3M |
| Interest Income | 0.5M |
| Pretax | -6.6M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -6.6M |
Rigel Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery and development of small molecule drugs for hematologic disorders, cancer, and rare immune diseases. Their flagship product, Tavalisse, is an oral spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia. The company's pipeline includes Fostamatinib, currently in phase III clinical trials for warm autoimmune hemolytic anemia and COVID-19 treatment, as well as other promising drug candidates targeting autoimmune, inflammatory, and oncology diseases. Rigel also generates revenue through research and license agreements with pharmaceutical companies for the development and commercialization of various drug candidates.
